Skip to main content
Premium Trial:

Request an Annual Quote

Promega, Tecan, Thermo Fisher Scientific, PerkinElmer

Premium
Promega Certifies Tecan’s Infinite 200 Microplate Readers as “DLReady”
 
Tecan said this week that Promega has certified its Infinite 200 multimode microplate readers as “DLReady.” According to Tecan, Promega has tested the instruments at the highest performance levels and standards for the Dual-Luciferase Reporter (DLR) assay system.
 
Promega’s proprietary reporter gene technology assays the activities of firefly and Renilla luciferase enzymes, providing quantitation of the reporter enzymes in microplate-based assays.
 
The Infinite 200 series is an automated and modular platform that offers eight different fluorescence, luminescence, and absorbance detection modes. The Infinite 200 series is suitable for sample measurements in 6- to 384-well plates, PCR plates, or cuvettes, and is available with either an advanced monochromator system (M200) or a filter system (F200).
 
The Infinite M200 includes Tecan’s quad4 monochromators technology, which the manufacturer said blocks stray light by up to one million times more than typical dual monochromator configurations.
 

 
Thermo Fisher Breaks Ground on New Facility in India to Support Local Pharmas
 
Thermo Fisher Scientific this week has broken ground on a $17 million facility in India designed to support its biopharmaceutical customers in the country.
 
Thermo Fisher said the 100,000-square-foot facility, located in the western city of Ahmadabad, will be responsible for packaging, distributing, and managing logistics for pharmaceutical samples that will be part of drug trials around the world.
 
The company expects to open the facility in the spring of 2008 and add approximately 100 employees in the first year of operation.
 
"Large pharmaceutical companies are focusing more and more on India for their future clinical research and development programs," Thermo Fisher CEO Marijn Dekkers said in a statement.
 
"They are looking to outsource their clinical trials management to partners who know how to work within changing regional and global clinical trial regulations,” he added.
 

 
Thermo Fisher Hints at Acquisition 'Opportunities' as Q3 Revenue, R&D Spend, and Profits Surge
 
Thermo Fisher Scientific this week said third-quarter revenues increased over 230 percent as R&D spending rose 52 percent and profit increased more than 300 percent.
 
The company also hinted that the “highly fragmented” market in which it plays “presents opportunities” to make additional acquisitions.
 
Thermo Fisher stressed that last year's results reflect Thermo Electron's operations before its merger with Fisher Scientific last November.
 
Total receipts for the three months ended Sept. 30 increased to $2.4 billion from $725 million year over year. On a pro-forma basis, the firm's third-quarter revenues grew 7 percent from $2.24 billion last year.
 
Thermo said revenue from its Analytical Technologies segment rose 12 percent to just over $1 billion, while receipts from the Laboratory Products and Services segment increased 4 percent to $1.44 billion.
 
R&D spending increased to $58.8 million from $38.6 million in the third quarter of 2006.
 
Thermo Fisher said profit rose to $218.5 million from $48.8 million in the year-ago period.
 
Thermo Fisher said it had around $830.8 million in cash and equivalents and $15.4 million in short-term investments as of Sept. 30.
 
The company said it is increasing its revenue guidance to between $9.6 billion and $9.65 billion for 2007 from its earlier prediction of between $9.5 billion and $9.55 billion.
 
The company also said that the “highly fragmented” life, lab, and health-sciences industry “presents opportunities for us to make acquisitions that create tremendous value by expanding our global reach, our commercial capabilities, or our technology portfolio.”
 

 
PerkinElmer's Q3 Revenues Rise 13 Percent Amid 'Strong Growth' in Gene Screening, Medical Imaging
 
PerkinElmer this week reported that third-quarter revenues increased 13 percent as R&D spending jumped 12 percent and profit ticked up about 3 percent.
 
Total receipts for the three months ended Sept. 30 increased to $435.7 million from $386.9 million year over year, PerkinElmer said.
 
Revenue for the company’s Life and Analytical Sciences business and its Optoelectronics unit swelled 13 percent year over year apiece, to $319.3 million and $116.3 million, respectively.
 
Feeding the increase was “strong growth in genetic screening, medical imaging, and service,” PerkinElmer said.
 
R&D spending in the quarter increased to $27.7 million from $24.8 million year over year.
 
PerkinElmer said profits in the period rose to $30.7 million from $29.8 million in the prior-year period.
 
PerkinElmer said it had around $160.9 million in cash and equivalents as of Sept. 30.
 
CEO Gregory Summe said in a statement that the company’s “investments in new products, services and geographic expansion continue to yield attractive results.” He did not elaborate in the statement.
 
The company said it expects fourth-quarter revenue to increase in the mid-teens with acquisitions and changes in foreign exchange rates contributing approximately 7 percent of that growth.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more